GlassScriptPhysician profile
David Edward Weng
NPI 1831154731
$21,004.35
in general payments reported to CMS, 2019-2025
53 companies · $4,109 in 2025
The $4,109 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,339 · 2020: $4,416 · 2021: $2,950 · 2022: $853 · 2023: $493 · 2024: $3,845 · 2025: $4,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,795 · Food and Beverage: $2,456 · Long Term Medical Supply Or Device Loan: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,795.00 |
| Food and Beverage | $2,455.66 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,691.12 | 2019-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $3,620.42 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Puma Biotechnology, INC. | $2,579.16 | 2019-2020 | |
| Beigene USA, INC. | $1,950.00 | 2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $1,544.05 | 2019-2025 | |
| Incyte Corporation | $1,209.55 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Rigel Pharmaceuticals, INC. | $1,019.08 | 2019-2020 | |
| Daiichi Sankyo INC. | $906.94 | 2021-2025 | Enhertu |
| Becton, Dickinson and Company | $800.00 | 2020 | |
| Janssen Biotech, INC. | $629.48 | 2019-2025 | Imbruvica, Carvykti, Erleada |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Glaxosmithkline, LLC. | $204.34 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Abbvie INC. | $203.72 | 2019-2025 | |
| Pfizer INC. | $202.58 | 2019-2025 | |
| Covis Pharma Gmbh | $200.00 | 2021 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure Gmbh | $200.00 | 2022 | |
| Merck Sharp & Dohme LLC | $190.33 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Celgene Corporation | $154.96 | 2019-2025 | Reblozyl |
| Genzyme Corporation | $115.93 | 2019-2025 | |
| Genentech USA, INC. | $110.82 | 2019-2025 | Venclexta, Itovebi, Gazyva |
| Amgen INC. | $97.86 | 2019-2025 | Evenity, Kyprolis, Blincyto |
| Tempus Ai, INC | $92.18 | 2025 | Xt Cdx |
| Astellas Pharma US INC | $78.78 | 2024-2025 | Padcev |
| Tesaro, INC. | $63.92 | 2019 | |
| Emd Serono, INC. | $62.01 | 2019-2024 | |
| Lilly USA, LLC | $58.42 | 2024-2025 | Verzenio, Jaypirca |
| Ipsen Biopharmaceuticals, INC | $48.67 | 2025 | Onivyde |
| Eisai INC. | $47.13 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $43.45 | 2025 | Libtayo |
| Gilead Sciences, INC. | $42.95 | 2019-2024 | |
| Secura Bio, INC. | $40.11 | 2021 | |
| Coherus Oncology, INC. | $39.60 | 2024-2025 | Loqtorzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $37.20 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $33.22 | 2019 | |
| Tersera Therapeutics LLC | $32.42 | 2025 | Xermelo |
| Taiho Oncology, INC. | $31.00 | 2024 | |
| Beone Medicines USA, INC. | $30.62 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $29.84 | 2025 | Besremi |
| Kite Pharma, INC. | $24.86 | 2025 | Yescarta |
| Kyowa Kirin, INC. | $22.76 | 2024 | Poteligeo |
| Janssen Pharmaceuticals, INC | $22.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.95 | 2025 | Iclusig |
| Mylan Institutional INC. | $21.60 | 2020 | |
| Bioprotect Medical, INC. | $21.13 | 2025 | Bioprotect Balloon Implant System |
| Alexion Pharmaceuticals, INC. | $19.97 | 2019 | |
| Servier Pharmaceuticals LLC | $19.57 | 2024 | |
| Adaptive Biotechnologies Corporation | $17.27 | 2024 | Clonoseq |
| Clinigen, INC. | $15.20 | 2019 | |
| Seagen INC. | $14.81 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.09 | 2025 | Vivimusta |
| Array Biopharma INC | $13.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.